• Head of EMEA Medical Affairs Therapy Area Strategy reporting into Head of EMEA Strategic Organisation.• Enterprise functional head of 1200 Medical Affairs team members across 79 legal entities in Europe, Middle East, Africa.• Direct line reports of 100+ team members across 3 levels. Responsibility for multiple therapy areas (Solid Tumour Oncology, Haemato-Oncology, Dermatology, Gastroenterology, Retina, Cardiovascular Medicine, Pulmonary Hypertension, Neuroscience, Early Portfolio and Evidence Generation). Oversight of all medical activities in product launches.• Designing and achieving EMEA Medical Affairs Change Transformation focusing on competitive mindset and behavioural culture change across the entire region. Delivering measurable high performance in Evidence Generation, Customer Engagement and People Development.• Voting member of key global and regional leadership teams driving strong Medical Affairs and cross functional partnership decisions on worldwide strategies, clinical development plans and evidence generation to best align with Worldwide and EMEA needs. • Final decision maker and accountability for EMEA Medical Affairs Evidence Generation budget management and timely delivery of extensive sponsored and investigator initiated study portfolio.• High personal scientific expertise and experience in Oncology, Haemato-oncology with regular involvement in new business development initiatives• Chairman of EMEA Diversity, Equity and Inclusion Council.

On International Development Assignment.• Regional Medical Affairs head across all therapy areas for EM Regional Medical team reporting into EM Managing Director. Active member of Emerging Markets Organising Committee (board level).• Direct line reports of 5 team members. Dotted line management of 6 EM cluster medical directors and head of functional organisation of 190+ Medical Affairs team members. • Co-lead of Gulf project reviewing involvement of Middle East and African countries in company sponsored clinical research. Culminating in creation of MEA non-core research mode and expansion of clinical research in these countries including first CAR-T study in Saudi Arabia. • Deep focus on people and talent development with first ever EMEA Medical Affairs director appointed from Emerging Markets.

• Regional (Europe, Middle East, Africa) medical affairs lead for extensive Haematology product portfolio (5 marketed assets including Darzalex, Imbruvica, Velcade + pipeline compounds including CAR-T)• Management of team of 16 with 6 direct and 10 second level reports• Led global roll out of ibrutinib therapy management programme• Led workstream to completely reshape Integrated Evidence Generation Planning into an EMEA wide strategic process with strong links into regional brand strategy

Responsibility for Global Medical Affairs for Enzalutamide:- Chair of Global Core Medical Team/Global Product Strategy Team- Chair of Joint Medical Affairs Committee (Alliance partnership with Medivation Inc)- Chair of Joint Life Cycle Management Team (Alliance partnership with Medivation Inc)- Oversight of Global Publications Team- Oversight of Global Phase IV studies and multi-regional cooperative group studies- Oversight of global prostate cancer advisory boards- Oversight of Global Medical Affairs Training activities- Overall responsibility for team budget management- Core team for review of pre-submission regulatory documentsLine management of a team of 3 directly reporting medical directors and 1 personal assistantCompletion of Certificate of Speciality Training in Pharmaceutical Medicine May 2014

Responsibility for Medical Affairs. European GU cancer portfolio (Torisel, Sutent, Inlyta):- Medical input for Inlyta EMA marketing approval and EU product launch- Managing EU budget for investigator initiated research, publications and medical education- Medical lead on all EU GU cancers medical activities including publications, advisory boards and congress satellite symposia- Leading matrix team of 3 team members and 5 virtual membersAdditional Global responsibilities:- Chair of global Sutent investigator initiated research scientific committeeHonorary Clinical Fellow in oncology - St Bartholomew's Hospital, London- Ongoing clinical practice on monthly basis in Joint Medical Oncology and Urological Oncology clinicDiploma in Pharmaceutical Medicine Dec 2010

UK medical affairs lead for renal cell and lung carcinomas- Main medical input in Sutent multiple technology appraisal achieving successful NICE approval in Mar 2009- Registered with PMCPA as medical final signatory